These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30879072)

  • 1. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis.
    Huijser E; van Helden-Meeuwsen CG; Groot N; Bodewes ILA; Wahadat MJ; Schreurs MWJ; van Daele PLA; Dalm VASH; van Laar JAM; van Hagen PM; Waris M; Kamphuis S; Versnel MA
    Rheumatology (Oxford); 2019 Jul; 58(7):1302-1303. PubMed ID: 30879072
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin.
    Lambers WM; de Leeuw K; Doornbos-van der Meer B; Diercks GFH; Bootsma H; Westra J
    Arthritis Res Ther; 2019 Dec; 21(1):260. PubMed ID: 31791398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis.
    Airò P; Ghidini C; Zanotti C; Scarsi M; Cattaneo R; Caimi L; Imberti L
    J Rheumatol; 2008 Nov; 35(11):2192-200. PubMed ID: 18843779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
    Katsumi S; Kobayashi N; Yamamoto Y; Miyagawa S; Shirai T
    Br J Dermatol; 2000 May; 142(5):1030-3. PubMed ID: 10809868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paediatric systemic lupus erythematosus: insights from translational research.
    Wright TB; Punaro M
    Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i24-i31. PubMed ID: 28375454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings: Immunohistological studies of the kidney in systemic lupus erythematosus and systemic sclerosis.
    Scott DG; Rowell NR
    Ann Rheum Dis; 1973 Nov; 32(6):592-3. PubMed ID: 4760486
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blastic lymphocyte transformation in lupus erythematosus and scleroderma].
    Pawińska M; Gliński W; Blaszczyk M; Wranicz A
    Przegl Dermatol; 1973; 60(2):161-6. PubMed ID: 4134109
    [No Abstract]   [Full Text] [Related]  

  • 9. A new tool for detection of type I interferon activation in systemic lupus erythematosus.
    Kirou KA; Kalliolias GD
    Arthritis Res Ther; 2010; 12(4):138. PubMed ID: 20815919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular and humoral factors of immunogenesis of sytemic lupus erythematosus and systemic scleroderma].
    Demin AA; Galenok VA; Kolesnuk VV; Finchenko AF
    Klin Med (Mosk); 1973 Nov; 51(11):100-4. PubMed ID: 4787290
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinico-immunologic parallels in patients with lupus erythematosus and scleroderma].
    Skripkin JK; Somov BA; Butov JS; Bereshnoj JZ
    Allerg Immunol (Leipz); 1972; 18(3):163-6. PubMed ID: 4269348
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cellular immunity in lupus erythematosus and scleroderma].
    Gliński W; Langner A; Pawińska M
    Przegl Dermatol; 1976; (6 Suppl):329-34. PubMed ID: 1032181
    [No Abstract]   [Full Text] [Related]  

  • 13. [Humoral and cellular immunity indices in lupus erythematosus and scleroderma].
    Butov IuS; Skripkin IuK; Koshevenko IuN
    Vestn Dermatol Venerol; 1978 Apr; (4):7-11. PubMed ID: 77599
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus.
    Kanayama Y; Kim T; Inariba H; Negoro N; Okamura M; Takeda T; Inoue T
    Ann Rheum Dis; 1989 Oct; 48(10):861-3. PubMed ID: 2818022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abnormal HLA-DR antigen expression in monocytes of patients with systemic lupus erythematosus and psoriasis vulgaris].
    Volk HD; Diezel W; Waschke SR; Barthelmes H; Grunow R; Fiebig H; Sönnichsen N
    Dermatol Monatsschr; 1985; 171(5):308-11. PubMed ID: 3926547
    [No Abstract]   [Full Text] [Related]  

  • 17. Type I interferon in systemic lupus erythematosus.
    Crow MK
    Curr Top Microbiol Immunol; 2007; 316():359-86. PubMed ID: 17969456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferon signature in systemic lupus erythematosus.
    Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
    Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Demonstration of antinuclear antibodies in the epidermis of patients with progressive systemic sclerosis, generalized lupus erythematosus and dermatomyositis].
    Lamas Robles C; Mejía Arreguín S; Orozco Medina JH; González Mendoza A
    Rev Invest Clin; 1984; 36(2):115-9. PubMed ID: 6385174
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistological studies, with anti-connective tissue and anti-immunoglobulin antisera, of the skin in lupus erythematosus and scleroderma.
    Rowell NR; Scott DG
    Br J Dermatol; 1975 Oct; 93(4):431-41. PubMed ID: 1081402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.